Autolus Therapeutics rises on US FDA approval for its cancer cell therapy

Autolus Therapeutics

08/11/2024 22:17

** U.S.-listed shares of drug developer Autolus Therapeutics
 6A3Ay.F   AUTL.O  rise 1.6% to $3.78 after the bell  
    ** U.S. FDA approves co's cancer cell therapy, Aucatzyl, for
patients with a type of rare blood cancer 
    ** The therapy is approved to treat adult patients with
relapsed B-cell precursor acute lymphoblastic leukemia, an
aggressive type of blood cancer 
    ** The therapy comes with a serious warning about the risk
of neurologic toxicities and cytokine release syndrome, a
dangerous aggressive immune system response
    ** Co says marketing authorization applications for the
therapy are currently being reviewed by regulators in both the
EU and the UK
    ** Co says Aucatzyl will be manufactured at its dedicated
commercial manufacturing site, the Nucleus, in Stevenage, UK
    ** Up to last close stock down 42.1% YTD 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com))